<DOC>
	<DOCNO>NCT00909428</DOCNO>
	<brief_summary>Evaluating effect VesicareR 10 mg ( Solifenacin , Astellas Inc ) QD , urgency level record filling phase urodynamic testing , patient overactive bladder . In pilot study , 10 patient overactive bladder syndrome ( OAB ) symptoms previously undergone urodynamic testing demonstrate detrusor overactivity currently receive anticholinergic drug , recruit clinic . Patients take Vesicare 10 mg daily 1 month , undergo repeat urodynamic test repeat evaluation urgency level fill phase .</brief_summary>
	<brief_title>Validation Real-Time Urodynamic Measure Urinary Urgency</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Have symptom urge mixed incontinence ( urge predominant ) desire treatment anticholinergic medication . Symptoms establish response MESA questionnaire , already complete part routine clinical care . Demonstrated detrusor overactivity without incontinence urodynamic testing , routine clinical care . Are able consent fill study document , complete repeat urodynamic test follow 4 week . Have treat anticholinergic medication previous month . Have elevate post void residual volume determine routine clinical care . Have urinary tract infection last month , determine history . Have untreated narrow angle glaucoma , patient history . Have know allergy intolerance VesicareR , determine patient history .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>overactive bladder syndrome</keyword>
	<keyword>low urinary tract</keyword>
	<keyword>urgency</keyword>
	<keyword>solifenacin</keyword>
	<keyword>pharmacotherapy</keyword>
	<keyword>urodynamic testing</keyword>
</DOC>